Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.
Galligan A, Iravani A, Lasocki A, Wallace R, Weppler AM, Sachithanandan N, Chiang C, Colman PG, Wentworth J, Spain L, Au-Yeung G, Lee B, Kay TWH, Hicks RJ, Sandhu S, Krishnamurthy B. Galligan A, et al. Among authors: au yeung g. Front Endocrinol (Lausanne). 2023 Nov 29;14:1295865. doi: 10.3389/fendo.2023.1295865. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38093958 Free PMC article.
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, Hunter MO, Akhurst T, Hofman MS, Lau PKH, Kee D, Au-Yeung G, Sandhu S, Hicks RJ. Iravani A, et al. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786. doi: 10.1007/s00259-020-04815-w. Epub 2020 Apr 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 32338306
Efficacy of immune checkpoint inhibitors for in-transit melanoma.
Nan Tie E, Lai-Kwon J, Rtshiladze MA, Na L, Bozzi J, Read T, Atkinson V, Au-Yeung G, Long GV, McArthur GA, Sandhu S, Saw R, Walpole E, Menzies A, Smithers M, Gyorki DE. Nan Tie E, et al. J Immunother Cancer. 2020 May;8(1):e000440. doi: 10.1136/jitc-2019-000440. J Immunother Cancer. 2020. PMID: 32376722 Free PMC article.
Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
Pizzolla A, Keam SP, Vergara IA, Caramia F, Thio N, Wang M, Kocovski N, Tantalo D, Jabbari J, Au-Yeung G, Sandhu S, Gyorki DE, Weppler A, Perdicchio M, McArthur GA, Papenfuss AT, Neeson PJ. Pizzolla A, et al. J Immunother Cancer. 2022 May;10(5):e004574. doi: 10.1136/jitc-2022-004574. J Immunother Cancer. 2022. PMID: 35550554 Free PMC article.
BRCA1 and BRCA2 carriers with breast, ovarian and prostate cancer demonstrate a different pattern of metastatic disease compared with non-carriers: results from a rapid autopsy programme.
Thorne H, Devereux L, Li J, Alsop K, Christie L, van Geelen CT, Burdett N, Pishas KI, Woodford N, Leditschke J, Izzath MHMA, Strachan K, Young G, Jaravaza RD, Madadin MS, Archer M, Glengarry J, Iles L, Rathnaweera A, Hampson C, Almazrooei K, Burke M, Bandara P, Ranson D, Saeedi E, McNally O, Mileshkin L, Hamilton A, Ananda S, Au-Yeung G, Antill Y, Sandhu S, Savas P, Francis PA, Luen S, Loi S, Jennens R, Scott C, Moodie K, Cummings M, Reid A, McCart Reed A, Bowtell D, Lakhani SR, Fox S. Thorne H, et al. Among authors: au yeung g. Histopathology. 2023 Jul;83(1):91-103. doi: 10.1111/his.14906. Epub 2023 Mar 31. Histopathology. 2023. PMID: 36999648
39 results